STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · VICO.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Vicore Pharma Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 45.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vicore Pharma Holding AB (publ)’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -SEK 0.51. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vicore Pharma Holding AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 1.75M+132.8% vs estimate |
| Q1 2025 | May 6, 2025 | -SEK 0.440.0% vs estimate | SEK 900.00K+20.0% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -SEK 0.51-42.93% vs estimate | SEK 5.10M |
|---|
| Q3 2024 | Nov 5, 2024 | -SEK 0.54 | SEK 0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 341.60+SEK 2.80 (+0.83%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
SEK 279.50+SEK 2.00 (+0.72%)
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
SEK 670.00SEK 0.00 (0.0%)
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.63% below the high.
SEK 319.40-SEK 0.80 (-0.25%)
BioArctic AB’s quoted price sits in the upper half of its reported 52-week range, 12.35% below the high.
SEK 71.25-SEK 0.30 (-0.42%)
Asker Healthcare Group AB’s quoted price sits in the lower half of its reported 52-week range, 25.44% below the high.
SEK 58.50-SEK 1.00 (-1.68%)
Elekta AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 12.29% below the high.
